A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

Running, not enrolling · Phase 4

Conditions studied: Generalized Pustular Psoriasis

In brief

This study is open to adults with a serious skin disease called generalized pustular psoriasis (GPP) who have repeated flares of GPP. The purpose of this study is to find out whether a medicine called spesolimab helps people with repeated flares of GPP. Participants are given a single dose of spesolimab as an infusion into a vein on the first day of an outbreak of GPP. They may be given a second dose 1 week later if doctors think it is helpful. They are also treated for additional GPP flares. During the time of the study, doctors regularly examine participants' skin for signs of GPP to see how well the treatment works and take blood samples. The doctors also regularly check participants' health and take note of any unwanted effects.

Key facts

Study ID: NCT06013969
Run by: LEO Pharma
People needed: 42
Starts: 2023-10-22
Expected to finish: 2026-09-02
Last updated by the study team: 2026-08-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients with a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation sub-score of 0 or 1 and a known and documented history of Generalized Pustular Psoriasis (GPP) (per European Rare And Severe Psoriasis Expert Network - ERASPEN - criteria), regardless of Interleukin 36 Receptor Antagonist (IL-36RN) gene mutation status or Patients with a GPP flare and a known and documented history of GPP (per ERASPEN criteria) regardless of IL-36RN gene mutation status.
Patients must have a history of frequent GPP flares in the past
Male or female patients, aged ≥18 years (if local legislation for age of consent differs, then local legislation will be followed) at screening
Signed and dated written informed consent prior to admission to the trial in accordance with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to start of any screening procedures
Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly

You may not qualify if…

Drug-triggered Acute Generalized Exanthematous Pustulosis (AGEP)
Patients with primary plaque psoriasis vulgaris without presence of pustules or with pustules that are restricted to psoriatic plaques
Patients with primary erythrodermic psoriasis vulgaris
Patients with SAPHO (Synovitis-acne-pustulosis-hyperostosis-osteitis) syndrome
Immediate life-threatening flare of GPP or requiring intensive care treatment, according to the investigator's judgement. Life-threatening complications mainly include, but are not limited to, cardiovascular/cytokine driven shock, pulmonary distress syndrome, or acute renal failure
Severe, progressive, or uncontrolled hepatic disease, defined as >3-fold upper limit normal (ULN) elevation in Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) or alkaline phosphatase, or >2-fold ULN elevation in total bilirubin
Presence of acute demyelinating neuropathy
Treatment with any drug considered likely to interfere with the safe conduct of the trial, as assessed by the investigator
Further exclusion criteria apply.

Where it is running

University of California Irvine — Irvine, California, United States
Red River Research Partners, LLC — Fargo, North Dakota, United States
Liverpool Hospital — Liverpool, New South Wales, Australia
Westmead Hospital — Westmead, New South Wales, Australia
Cliniques Universitaires Saint-Luc — Brussels, Belgium
Hospital Universitario Evangelico Mackenzie — Curitiba, Brazil
Faculdade de Medicina do ABC — Santo André, Brazil
Southern Medical University Dermatology Hospital — Guangzhou, China
Shanghai Skin Disease Hospital — Shanghai, China
Shanghai Tenth People's Hospital — Shanghai, China
HOP Trousseau — Chambray-lès-Tours, France
HOP Saint-Louis — Paris, France
Universitätsklinikum Frankfurt — Frankfurt am Main, Germany
Klinikum der Universität München AÖR — München, Germany
SP medical college and associated group of hospitals — Bikaner, India
Nkp Salve Institute of Medical Sciences and Lata Mangeshkar Hospital — Nagpur, India
ASST degli Spedali Civili di Brescia — Brescia, Italy
Hospital Selayang — Batu Caves, Malaysia
Hospital Pulau Pinang-Pulau Pinang-21953 — Georgetown Pulau Pinang, Malaysia
Hospital Sultanah Aminah — Johor Bahru, Malaysia
Hospital Sultan Ismail — Johor Bahru, Malaysia
Hospital Kuala Lumpur — Kuala Lumpur, Malaysia
Hospital Putrajaya — Putrajaya, Malaysia
Sunway Medical Centre — Selangor Darul Ehsan, Malaysia
National University Hospital-Singapore-42005 — Singapore, Singapore

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.